Brief: Sutro Biopharma Announces Presentation Of Data For Luvelta From Phase 1 Dose-Expansion Study In Endometrial Cancers At ESMO 2023
22/10/2023 09:28
Oct 22 (Reuters) - Sutro Biopharma Inc STRO.O :
* SUTRO BIOPHARMA ANNOUNCES PRESENTATION OF DATA FOR
LUVELTAMAB
TAZEVIBULIN (LUVELTA) FROM THE PHASE 1 DOSE-EXPANSION STUDY IN
ENDOMETRIAL CANCERS AT ESMO 2023
* SAFETY PROFILE WAS CONSISTENT WITH PRIOR DATA IN PATIENTS
WITH
PLATINUM-RESISTANT OVARIAN CANCER
* LUVELTA DEMONSTRATED ENCOURAGING PRELIMINARY ANTI-TUMOR
ACTIVITY
(29% RESPONSE RATE) IN LATE-STAGE PATIENTS
Source text for Eikon: ID:nGNX4JfGYK
Further company coverage: STRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sutro Biopharma
See all newsBrief: Sutro Biopharma Announces First Patient Dosed In Phase 1 Trial Of STRO-006
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Sutro Biopharma tumbles after missing estimates